Claudia Parisi, Praticienne Specialiste at Centre Antoine Lacassagne and Editorial Board Member at BMJ Oncology, shared a post on LinkedIn:
“How fast runs cancer care?
Only 3 years ago I was resident senior in the phase 1 dpt and we realized first infusions of anti-DLL3 BiTE Tarlatamab in humans, with apprehension related to CRS.
Since that we have learned how to manage toxicity, observed OS benefit from the ph 3 DeLLphi-304 trial in pretreated SCLC pts and we now have evidence on drug resistance from case reports.
That’s amazing. That’s why we shouldn’t give up.”
Title: Brief Report: Low Delta-like Ligand 3 expression and T Cell Exhaustion Drive Resistance to Tarlatamab combined with anti-PD-1 in Small-Cell Lung Cancer
Authors: Akito Fukuda, Tomoyo Fukami, Kotaro Nomura, Jumpei Kashima, Shogo Kumagai, Yasushi Goto, Yasushi Yatabe, Tatsuya Yoshida
Read The Full Article
Other articles featuring Claudia Parisi on OncoDaily.